Proteonomix Inc. [OTC:PROT]

Proteonomix is a biotechnology company focused on developing therapeutics based upon use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, National Stem Cell, PRTMI, The Sperm Bank of New York and THOR BioPharma. Proteoderm, Inc. is wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). National Stem Cell, Inc. is Proteonomix’s subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (“PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

The Proteonomix Mission

Their mission is to focus upon the development of therapies based upon the use of human stem cells and their derivatives, particularly in the areas of diabetes and cardiac diseases. They primarily employ bone marrow, pancreatic, and umbilical cord blood derived cells in a process of identification, separation, expansion and delivery towards treatment of diseases previously considered incurable. It is their further goal to deliver these therapies to the widest possible spectrum of patients both geographically and economically in the minimum time.

Primary Focus

They are primarily focused on developing therapies and products based upon the use of human stem cells and their derivatives with an initial focus on diabetes and cardiac diseases.

Stem cell therapy provides much promise for the treatment of diseases previously regarded as incurable.
Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These diseases include but are not limited to cancer, heart disease, diabetes, and autoimmune conditions. Stem cell therapy provides much promise for the treatment of diseases previously regarded as incurable.

StromaCel™ Cardiac Treatment
They are developing their Post Myocardial Infarction treatment, StromaCel™. This treatment is taken intravenously in the first 14 days following an infarction to assist to rebuild the underlying vascular tissuein order to increase cardiac muslcle recovery. They are currently seeking funding to make application for FDA Clinical trials on this promising treatment.

Diabetes Research
They have been in research and development for many years on a treatment for all forms of diabetes. Recent breakthroughs in their research have encouraged us to seek funding for large animal trials in anticipation of Phase 1 trials to follow.

Other Areas of Development
Proteonomix also looks at overall health and wellness. As their Proteoderm products comes to market for skin rejuvination and anti-aging, we are also developing additional products to improve the quality of their clients lives.

Management

Michael Cohen

President, Chief Executive Officer, Chairman of the Board

Michael Cohen has served as their President, Chief Executive Officer and Chairman of their board of directors since September 12, 2006. Michael Cohen began his career as a paramedic for NYC EMS in 1989. He joined Americorp Securities as a Vice President in its mergers and acquisitions department in 1994. He was instrumental in launching a number of successful IPOs at Americorp Securities. He was recruited by Dafna Construction in 1995 as its CFO and played a principal role in its growth and subsequent purchase. In 1997, Mr. Cohen joined Citigroup as a Vice President of Corporate Finance and managed a department in the risk management division of Salomon Smith Barney. In 2002, Mr. Cohen founded National Stem Cell Inc, their operating subsidiary. Mr. Cohen serves as our Chairman of the Board and President as well as the Principal Investigator for most of their therapeutic developments. Mr. Cohen attended Skidmore College and graduated with a Bachelor of Science from Haifa University in 1988.

Ian McNiece

Ph.D., Chief Scientific Officer, Director

Dr. McNiece received his PhD in 1986 from the University of Melbourne undertaking his thesis work in studies of blood cell development at the Peter MacCallum Cancer Institute in Melbourne, Australia. He moved to the USA in July of 1986 to the University of Virginia as a postdoctoral fellow. In August 1998 he started working at Amgen Inc, as a Research Scientist and then as a Laboratory Head. In September 1997, he left Amgen and moved to the University of Colorado as the Director of Research in the Bone Marrow Transplant Program. Subsequently, he moved to Johns Hopkins University as a Professor of Oncology and Laboratory Director of the Graft Engineering Laboratory from January 2003 to May 2007. This laboratory is responsible for all processing of bone marrow, peripheral blood progenitor cell (PBPC) products and cord blood products for transplantation of cancer patients. He was actively involved in optimization of cellular grafts for patient treatment and the translation of basic research to clinical treatment. In July, 2007 he joined the Stem Cell Institute at the University of Miami as Director of the Experimental and Clinical Cell-Based Therapies and is presently Professor of Medicine at the University of Miami.

Jason Isaacs

Secretary

Jason Isaacs joined as Secretary in June of 2010. Mr. Isaacs brings over thirteen years of legal experience. Mr. Isaacs is General Counsel of Green Hills Software, Inc., the largest independent provider of real time operating systems and embedded software development tools. Mr. Isaacs has a wide base of legal experience managing and protecting intellectual property resources, negotiating technology transactions with major corporations and governments, and complying with applicable laws and regulations. Mr. Isaacs practiced law at Brobeck Phleger & Harrison LLP and Heller Ehrman LLP in San Diego, specializing in technology transactions, licensing arrangements and business litigation in his representation of high growth and venture backed companies. Mr. Isaacs received his law degree from Harvard Law School, cum laude, and a B.A. from Brown University, magna cum laude, Phi Beta Kappa.

Steven Byle

Director

Steven Byle joined their board of directors on January 5, 2009. Mr. Byle brings twenty years of experience in technology development and corporate management in the international market.  Mr. Byle is a successful entrepreneur, engineer, and patent attorney for a diverse array of international, public and private, ventures. Mr. Byle is presently the Vice President of Technology for Dockwise, a public energy services company on the Euronext Amsterdam exchange (DOCKW:NA) with annual revenues exceeding US $500 million.  Mr. Byle is also a founder and Member of the Board for a diverse group of companies, including: Pantheon Energy, an alternative energy company in Europe, Core International Group, a Cyprus company performing international manufacturing, logistics and distribution with plants in India and Malaysia, and Texas Auto Superstore, an online auto dealer in the United States. Mr. Byle speaks Spanish and Mandarin Chinese fluently, holds a J.D. degree with Honors in law from the University of Texas School of Law, specializing in Intellectual Property Law, and holds a B.S. degree in Engineering from the University of Michigan, summa cum laude as a prestigious Angell Scholar.

Roger Fidler Esq.

Corporate Council

Mr. Fidler has been engaged in the private practice of law since 1983, specializing in corporate and securities law. Mr. Fidler was the sole director, President, Chief Executive and Financial Officer of Global Agri-Med Technologies, Inc., a corporation that is publicly traded in the pink sheets, since inception in October 28, 1999 until January 11, 2010. Mr. Fidler has previously served on the Boards of Directors and as an officer of several other publicly held corporations, including Diehl Graphsoft, Inc., D-Lanz Development Group, Inc., the Leonard Swindbourne Acquisition Corp., and numerous private companies. Mr. Fidler received a B.S. degree in Physics from Dickinson College, Carlisle, Pennsylvania in 1972; a Masters of Science degree from the University of Illinois at Champaign-Urbana, Illinois in 1974; and a Juris Doctor from the University of South Carolina in 1977 where he was a member of the Law Review. He is a member of the bars of New Jersey, New York and the District of Columbia and has practiced before the federal and state courts in New York and New Jersey as well as pro hac vice in cases before Federal District Courts in Kentucky and Florida. In addition he is a patent attorney authorized to practice before the United States Patent and Trademark Office.

Intellectual Properties and Patent Applications.

Through their operating subsidiary, National Stem Cell, we have developed a catalog of intellectual properties and patent applications. These technologies are designed to work together in a synergistic fashion. Their initial focus in stem cell therapeutics is to achieve a leadership position in:

The Development of Identification Biomarkers
A biomarker is a substance used as an indicator of a biological state which refers to the complete range of genes found in biological structure and processes of the living body, including the nervous system, the endocrine system, and their senses of sight, hearing, taste, smell, and touch. It is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention) cell derivatives, and cellular proteins.

Expansion Technology
Proteonomix is developing a unique growth medium that allows expansion far beyond the traditional 10:1 achieved in conventional methods before cellular replication errors make it nonviable. This technology is of benefit to any treatment or process that might be improved by drastically increased concentrations or numbers of cells.

Cryopreservation
Proteonomix is developing an innovative cryopreservation technique resulting in substantial reduction in lost cells during the freezing and thawing process. This technology is of benefit where it is advantageous to store cellular material for later use, to maintain stock, or to perform long distance transportation.

Anti-Inflammatory
Proteonomix’s StromaCel™ cellular materials has given some indications as a general anti-inflammatory. We are looking for partners wishing to explore this indication for conditions other than myocardial infarction

Diabetes Research

Cells that they are able to isolate will substantially reduce rejection when transplanted into the liver of the same diabetic patient.
They have identified stem cells in the human pancreas and have applied for patents for cell surface markers (the molecules present on the surface of each cell which define the cell on what receptors are present – a technique often used to associate cells with certain immune functions) for these pancreatic stem cells as well as methods for their isolation.

Based on the fact that these cells are autologous (from same person) rather than from a non-related donor, they anticipate that the cells that they are able to isolate will substantially reduce rejection when transplanted into the liver of the same diabetic patient. The company is performing further research in this area with the University of Miami.

AFFILIATES

Clinical Applications of Regenerative Medicine.
Proteonomix Institutes

Proteonomix is presently forming an international network of Stem Cell Laboratories, following their proprietary Proteonomix Regenerative Translational Medicine Institute (PRTMI) business model.

These institutes focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. The mission of these Institutes is to provide a seamless transition between Proteonomix’s laboratory activities and the local patient care facility. This involves development of clinical protocols, manufacturing of cellular materials for clinical use, monitoring compliance of clinical trials while participating on a global level in these processes.

Distribution of Anti-Aging and Wound Care Products.

Proteoderm Dermatologist
Their subsidiary, Proteoderm is currently forming a network of dermatologist for the distribution of its anti-aging and wound care products.

The networks are expected to activate in the fourth quarter 2010 in the United States and first quarter 2011 in the UAE and regional GCC countries.

For information on becoming a network doctor, or to inquire about starting your own network in a region that is currently not served, please contact us.

Joint Research in Clinical Exploration
Proteonomix’s Technologies

Their technologies have potential efficacy and usefulness in a wide range of applications. They are currently looking for owners of complementary technologies for joint research or affiliates interested in clinical exploration of additional indications for their own technologies.

Expansion Technology: Proteonomix is developing a unique growth medium that allows expansion far beyond the traditional 10:1 achieved in conventional methods before cellular replication errors make it nonviable. This technology is of benefit to any treatment or process that might be improved by drastically increased concentrations or numbers of cells.

Cryopreservation: Proteonomix is developing an innovative cryopreservation technique resulting in substantial reduction in lost cells during the freezing and thawing process. This technology is of benefit where it is advantageous to store cellular material for later use, to maintain stock, or to perform long distance transportation.

Anti-Inflammatory: Proteonomix’s StromaCel™ cellular materials has given some indications as a general anti-inflammatory. They are looking for partners wishing to explore this indication for conditions other than myocardial infarction.

Please read our full Disclaimer here: http://www.northstarstocks.com/disclaimer/
Northstarstocks.com expects to be compensated by a third party for Proteonomix Inc. [OTC:PROT] advertising services.